======= GTF2IRD1 =======
== Gene Information ==
* **Official Symbol**: GTF2IRD1
* **Official Name**: GTF2I repeat domain containing 1
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=9569|9569]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9UHL9|Q9UHL9]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=GTF2IRD1&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20GTF2IRD1|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/604318|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: The protein encoded by this gene contains five GTF2I-like repeats and each repeat possesses a potential helix-loop-helix (HLH) motif. It may have the ability to interact with other HLH-proteins and function as a transcription factor or as a positive transcriptional regulator under the control of Retinoblastoma protein. This gene plays a role in craniofacial and cognitive development and mutations have been associated with Williams-Beuren syndrome, a multisystem developmental disorder caused by deletion of multiple genes at 7q11.23. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2010].
* **UniProt Summary**: May be a transcription regulator involved in cell-cycle progression and skeletal muscle differentiation. May repress GTF2I transcriptional functions, by preventing its nuclear residency, or by inhibiting its transcriptional activation. May contribute to slow-twitch fiber type specificity during myogenesis and in regenerating muscles. Binds troponin I slow-muscle fiber enhancer (USE B1). Binds specifically and with high affinity to the EFG sequences derived from the early enhancer of HOXC8 (By similarity). {ECO:0000250, ECO:0000269|PubMed:11438732}.
|GTF2I|
|transition between slow and fast fiber|
|regulation of skeletal muscle adaptation|
|regulation of muscle adaptation|
|regulation of muscle system process|
|transcription by RNA polymerase II|
|regulation of system process|
|transcription, DNA-templated|
|nucleic acid-templated transcription|
|RNA biosynthetic process|
|DNA-binding transcription factor activity|
|nucleobase-containing compound biosynthetic process|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|organic cyclic compound biosynthetic process|
|DNA binding|
|DNA-binding transcription factor activity, RNA polymerase II-specific|
|cellular nitrogen compound biosynthetic process|
|RNA metabolic process|
|cellular macromolecule biosynthetic process|
|macromolecule biosynthetic process|
|gene expression|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp226|Cerivastatin 0.15μM R05 exp226]]|-2|
|[[:results:exp95|BI-2536 0.0042μM R03 exp95]]|1.8|
No correlation found to any other genes in chemogenomics.
Global Fraction of Cell Lines Where Essential: 0/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/26|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 10635
* **Expression level (log2 read counts)**: 4.68
{{:chemogenomics:nalm6 dist.png?nolink |}}